Replimune Group, Inc. (REPL) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-06-29

How it makes money

It has never generated any product sales and depends entirely on future regulatory approvals to commercialize its oncolytic immunotherapy product candidates.

As a clinical-stage biotechnology company, it has devoted all of its resources to developing its proprietary RPx platform, conducting research and development, and raising capital. It does not have any products approved for sale and has never generated any revenue from product sales.

Its future earnings will depend on the successful clinical development and eventual commercialization of its product candidates, such as RP1 and RP2, which are designed to selectively replicate in and kill tumors while activating the patient-specific immune system.

What protects it: the moat

It relies on its intellectual property position and proprietary RPx platform to protect its technology, though it faces intense competition in biopharmaceuticals.

Management claims that its proprietary RPx platform, based on an engineered strain of herpes simplex virus 1, provides a competitive advantage through its dual local and systemic activity. However, it faces significant risks from competitors developing products more quickly or marketing them more successfully.

Its intellectual property position depends on the scope of protection it can establish and maintain for its product candidates, as well as avoiding potential infringement claims from third parties.

What growth costs

It finances its operations primarily through equity offerings and loans, accumulating $1,132.9 million in net proceeds since its initial public offering.

Since its inception and initial public offering on July 20, 2018, it has raised an aggregate of approximately $1,132.9 million in net proceeds to fund operations. This includes $101.2 million from its IPO, $862.0 million from five separate follow-on offerings, $96.7 million from a private placement, and $73.0 million from at-the-market offerings.

Its net losses were $313.9 million and $247.3 million for the years ended March 31, 2026 and 2025, respectively, resulting in an accumulated deficit of $1,262.5 million as of March 31, 2026. These costs stem primarily from research and development activities and administrative support.

What could damage it

Regulatory rejection or delays in obtaining approval for its product candidates would prevent commercialization and permanently impair its ability to generate revenue.

Because it relies entirely on the successful regulatory approval of its clinical-stage product candidates, any failure or delay in clinical trials or regulatory review processes—such as the complete response letters received for its Biologics License Application—halts product commercialization.

Without approved products to generate sales, it must continue to rely on external financing to cover its substantial operating losses, threatening its long-term financial viability if capital markets or financing sources become unavailable.

About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Other companies in Biotechnology